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Stem cell factor (SCF), the ligand of c-kit, is a key cytokine for hematopoiesis. 
Hematopoietic precursors express c-kit, whereas differentiated cells of hematopoietic 
lineage are negative for this receptor, with the exception of NK cells, mast cells, and 
a few others. While it has long been recognized that dendritic cells (DCs) can express 
c-kit, several questions remain concerning the SCF/c-kit axis in DCs. This is particularly 
relevant for DCs found in those organs wherein SCF is highly expressed, including the 
bone marrow (BM). We characterized c-kit expression by conventional DCs (cDCs) from 
BM and demonstrated a higher proportion of c-kit+ cells among type 1 cDC subsets 
(cDC1s) than type 2 cDC subsets (cDC2s) in both humans and mice, whereas similar 
levels of c-kit expression were observed in cDC1s and cDC2s from mouse spleen. 
To further study c-kit regulation, DCs were generated with granulocyte-macrophage 
colony-stimulating factor (GM-CSF) from mouse BM, a widely used protocol. CD11c+ 
cells were purified from pooled non-adherent and slightly adherent cells collected after 
7 days of culture, thus obtaining highly purified BM-derived DCs (BMdDCs). BMdDCs 
contained a small fraction of c-kit+ cells, and by replating them for 2 days with GM-CSF, 
we obtained a homogeneous population of c-kit+ CD40hi MHCIIhi cells. Not only did 
BMdDCs express c-kit but they also produced SCF, and both were striking upregulated 
if GM-CSF was omitted after replating. Furthermore, a small but significant reduction in 
BMdDC survival was observed upon SCF silencing. Incubation of BMdDCs with SCF did 
not modulate antigen presentation ability of these cells, nor it did regulate their membrane 
expression of the chemokine receptor CXCR4. We conclude that the SCF/c-kit-mediated 
prosurvival circuit may have been overlooked because of the prominent use of GM-CSF 
in DC cultures in vitro, including those human DC cultures destined for the clinics. We 
speculate that DCs more prominently rely on SCF in vivo in some microenvironments, 
with potential implications for graft-versus-host disease and antitumor immunity.
Keywords: bone marrow-derived dendritic cells, conventional dendritic cell subsets, bone marrow, dendritic cell 
survival, dendritic cell homeostasis, gM-csF, stem cell factor
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inTrODUcTiOn
Dendritic cells (DCs) are cells of hematopoietic origin that 
develop in the bone marrow (BM) and play a key role in immu-
nity and tolerance. Resting DCs are scattered as sentinels in 
tissues throughout the body, contributing to maintain tolerance 
in healthy conditions (1, 2). Upon pathogen entry, tissue DCs 
become activated, uptake and process antigens, and acquire an 
increased capacity to migrate to draining lymph nodes (LNs). 
Changes in migratory behavior of activated DCs are reflected by 
modulation of chemokine receptors, for instance, upregulation 
of CCR7, the receptor for CCL19/21, and of CXCR4, the receptor 
for CXCL12 (3–6). Fully activated or mature DCs act as profes-
sional antigen-presenting cells (APCs), with the unique ability 
to prime naïve CD4 and CD8 T cells (2, 7). Furthermore, DCs 
orchestrate immune response by producing a wide array of mem-
brane molecules, cytokines, and chemokines (8). After activation, 
DCs are destined to die by apoptosis or necroptosis, depending 
on the maturating stimuli (9, 10). DC survival is also regulated by 
several inflammatory cytokines, including type I interferon (IFN) 
and IL-15 (11, 12).
Distinct DC subsets have been identified (2, 13). Classical or 
conventional DCs (cDCs) are specialized in antigen processing 
and presentation, whereas plasmacytoid DCs (pDCs) produce 
high levels of type I IFN in response to viral infection (2). In 
mice, cDCs express high levels of CD11c integrin, while pDCs 
have an intermediate expression of this marker (14). At least two 
cDC subsets have been identified: the most abundant type 2 cDC 
subset (cDC2) expresses CD11b in mice and CD1c in humans; 
the type 1 cDC subset (cDC1) expresses CD8α and/or CD103 in 
mice and CD141 in humans (14). Under pathological conditions, 
novel DC subsets could appear, for example, monocyte-derived 
inflammatory DC (15). Different sets of chemokine receptors 
are expressed by DC subsets, for example, CX3CR1, the receptor 
for fractalkine, is expressed by pDCs, human blood cDC2, and 
kidney DCs (16–18).
Peripheral DCs have a finite life span (19). DCs mostly derive 
from common myeloid progenitors (CMPs) in the BM, with 
some contribution by common lymphoid precursors (2). Both 
FMS-like tyrosine kinase 3 ligand (Flt3-L) and granulocyte-
macrophage colony-stimulating factor (GM-CSF) regulate DC 
development and maintenance of normal differentiated DC 
numbers (20–22). In the absence of GM-CSF, cDC numbers in 
spleen and LN were decreased about 2- and 4-fold, respectively; 
cDC reduction was more prominent in Flt3-L ko mice, and 
pDCs were also greatly impaired in these mice (21). Data in 
Flt3 ko and Flt3/GM-CSF receptor double ko mice supported a 
specific role for Flt3 signaling in cDC maintenance (23). Notably, 
some residual cDCs were found in the spleen and BM of Flt3-L 
ko mice, and they were still present in Flt3-L/GM-CSF double ko 
mice (21). Altogether, these results suggest that some unknown 
mechanisms might contribute to differentiated DC survival in 
lymphoid organs (21).
Dendritic cells can express c-kit, the receptor for stem cell 
factor (SCF) (13, 24). In a mouse model of allergic asthma, it was 
found that c-kit was expressed by DCs from lung of mice immu-
nized intranasally with OVA/cholera toxin or OVA/CpG, but not 
by lung DCs from untreated mice (25). Activation of SCF/c-kit 
axis in DC promoted Th2 and Th17 but not Th1 response (25–27). 
Under physiological conditions, lymphoid-tissue cDCs but not 
pDCs express c-kit (13, 14, 28). Despite increasing knowledge of 
location-specific DC characteristics, several questions regarding 
c-kit expression by DCs remain, for instance whether DCs from 
different lymphoid organs display differences in c-kit expression, 
and whether SCF binding to c-kit plays a role in DC homeostasis 
particularly in those organs wherein SCF is highly expressed, 
such as the BM (29).
In the BM, fibroblasts, endothelial cells, and other cell types 
produce SCF, an essential cytokine for hematopoiesis, that is also 
required for germ cell and melanocyte development (29–32). 
Soluble and membrane isoforms of SCF are generated as a result 
of alternative splicing and proteolytic cleavage (33). Binding of 
SCF to its membrane receptor c-kit (also called CD117) activates 
intracellular signaling molecules including PI-3 kinase, PLCγ, 
src-family kinases, and regulating cell survival, proliferation, 
adhesion (32–34).
In this paper, we evaluated c-kit expression by DC subsets in 
mouse and human BM and studied SCF/c-kit axis in DCs gener-
ated in vitro from mouse BM.
MaTerials anD MeThODs
cytokines and culture Media
Recombinant mouse SCF and Flt3-L were purchased from 
Immunotools (Friesoythe, Germany), recombinant mouse 
GM-CSF from Peprotech (Rocky Hill, NJ, USA). Opti-MEM 
Medium (Thermo Fisher Scientific, Waltham, MA, USA) was 
supplemented with glutamine, penicillin/streptomycin, 50  µM 
β-mercaptoethanol (Complete Opti-MEM medium). Complete 
Opti-MEM medium was not supplemented with any serum, 
except in the cultures with OT-1 and OT-2 cells, as indicated. 
RPMI Medium 1640 (Sigma-Aldrich, Milan, Italy) was supple-
mented as above, plus 10% heat-inactivated fetal calf serum (FCS) 
(complete RPMI medium). Opti-MEM is an optimized version 
of MEM containing insulin and transferrin, but does not contain 
GM-CSF, Flt3-L, SCF, or other cytokines (personal communica-
tion from Thermo Fisher Scientific Technical Support).
Mouse sample collection and Preparation
Female C57BL/6J (B6) and OT-2 TCR transgenic mice were 
purchased from Charles River and housed at the animal facil-
ity of Istituto Superiore di Sanità of Rome (ISS), according to 
institutional guidelines (DL116/92 and 26/2014). Female OT-1 
TCR transgenic mice were kindly provided by Dr. M. R. Castrucci 
(ISS). The OT-1 transgenic TCR recognizes the Kb-restricted OVA 
257–264 peptide (35), while the OT-2 transgenic TCR recognizes 
the I-Ab-restricted OVA 323-339 peptide (36). CX3cr1gfp/+ 
and CX3cr1gfp/gfp B6 mice were purchased from JAX Mice and 
Services (Bar Harbor, ME, USA) (37). Mice were sacrificed at 
5–16  weeks of age and spleen, peripheral, and mesenteric LNs 
and BM obtained as we previously described (38, 39). In some 
experiments, CD11c+ cells were enriched from either spleen or 
BM with anti-CD11c magnetic microbeads (Miltenyi Biotec, 
Bergisch Gladbach, Germany).
3Barroeta Seijas et al. SCF/c-Kit Axis in Dendritic Cells
Frontiers in Immunology | www.frontiersin.org February 2017 | Volume 8 | Article 147
BM-Derived Dcs (BMdDcs)
We generated DCs from BM cells as previously described (40, 
41), with few modifications. Briefly, 10–15 × 106 BM cells were 
cultured in complete RPMI medium with 20 ng/ml of GM-CSF 
in Petri dishes (BD Falcon, BD Biosciences, San Jose, CA, USA). 
After 3  days, fresh medium with GM-CSF was added. At day 
7, we collected non-adherent and slightly adherent cells after 
detachment with PBS 3 mM EDTA. CD11c+ cells were purified 
with anti-CD11c magnetic microbeads (Miltenyi Biotec), thus 
obtaining BMdDCs. In some experiments, DCs were generated 
by culturing BM cells with Flt3-L at 100 ng/ml for 8 days, as previ-
ously described (42).
antigen Presentation assay
OT-1 and OT-2 mice were sacrificed and single cell suspensions 
were obtained from spleen and LNs. OT-1 CD8+ and OT-2 CD4+ 
cells (≥87% pure) were obtained after incubation with anti-
CD8β.2 fluorescein isothiocyanate (FITC) monoclonal antibody 
(mAb) (BD) and CD4 FITC mAb (BD), respectively, followed by 
positive selection with anti-FITC magnetic microbeads (Miltenyi 
Biotec). Cells were labeled for 8 min at room temperature with 
2.5  µM carboxyfluorescein diacetate succinimidyl ester (CFSE, 
Molecular Probes, Eugene, OR, USA). For antigen presentation 
assays, BMdDCs were kept for 2  days in complete Opti-MEM 
medium with GM-CSF at 20  ng/ml, then incubated for 5  h 
with Ovalbumin (OVA, Hyglos GmbH, Resenburg, Germany) 
at 0.2 mg/ml, in the presence or not of SCF at 100 ng/ml. After 
extensive washings, BMdDCs (200–250 ×  103  cells/well) were 
cocultured in flat-bottom 96-well plates in complete Opti-MEM 
medium with 5% FCS with either purified CFSE-labeled OT-1 
CD8+ (700–750 × 103 cells/well) or purified CFSE-labeled OT-2 
CD4+ (200 ×  103  cells/well) cells for 3  days. CFSE dilution by 
TCR+ CD8+ and TCR+ CD4+ cells was evaluated by flow cytom-
etry (43–45).
Membrane staining and Flow cytometry
Cell membrane staining was performed with fluorochrome-
conjugated mAbs, after blocking with anti-FcγR (clone 2.4G2) 
mAb. The following mAbs were used (clone indicated in paren-
theses): anti-CD11c (HL3), anti-I-Ab or MHCII (M5/114.15.2) 
anti-CD40 (HM40-3), anti-CD11b (M1/70), anti-CD8α 
(53-6.7), anti-CD3 (145-2C11), anti-NK1.1 (PK136), anti-c-kit 
(2B8), anti-TCRβ (H57-597); anti-CD4 (RM4-4); anti-CD8β.2 
(53-5.8); anti-CXCR4 (2B11) [from BD Biosciences; Biolegend, 
San Diego, CA, USA; Miltenyi Biotec; eBioscience; conjugated 
with FITC, phycoerythrin (PE), peridinin chlorophyll protein 
(PerCP)-Cy5.5, PE-Cy7, Alexa 647, APC, APC-Vio770; APC-
H7]. Dead cells were excluded with Propidium Iodide (PI, 
Sigma-Aldrich). Samples were analyzed by FACSCanto I and 
II (BD Biosciences). Data were analyzed using FlowJo software, 
v.9.7.6 (FlowJo, Ashland, OR, USA).
real-time Pcr
Total RNA was extracted by TriReagent (Sigma-Aldrich). 
One microgram of total RNA was used for cDNA first-strand 
synthesis according to the manufacturer’s protocol for Moloney 
MLV reverse transcriptase (Promega, Madison, WI, USA). 
Real-time PCR was performed using the ABI Prism 7900 
sequence detection system (Applied Biosystems, Foster City, 
CA, USA). cDNAs were amplified in triplicate with primers 
for c-kit (Mm00445212_m1), SCF (Mm00442972_m1), and 
hprt-1 (Mm00446968 m1) (Applied Biosystems, Thermo Fisher 
Scientific), all conjugated with fluorochrome FAM. Relative 
expression of each gene versus hprt-1 was calculated according 
to the 2−∆∆Ct method.
Western Blot
Immunoblotting was performed as we previously described, 
after cell lysis with 1% Triton X-l00, 0.1% SDS Tris buffer 
containing protease inhibitor cocktail (Sigma-Aldrich) and 
the phosphatase inhibitors NaF, Na3VO4, phenylmethylsulfonyl 
fluoride (46). Equal amounts of proteins were separated by 10% 
SDS-PAGE, transferred onto PVDF membrane by Trans-Blot 
TurboTM Transfer System (Bio-Rad Laboratories), and probed 
with anti-phospho-AKT (Ser 473), anti-AKT and anti-β-actin 
antibodies (Cell Signaling Technology, Danvers, MA, USA). 
Chemiluminescence detection was performed by a CCD 
camera gel documentation system (ChemiDocXRS, Bio-Rad 
Laboratories, Hercules, CA, USA).
elisa
BM-derived DCs were lysed as above without the phosphatase 
inhibitors. BMdDC culture supernatants (100  µl/well) and 
BMdDC lysates (25 µg of cell lysate/well) were tested by mouse 
SCF ELISA kit (Boster Immunoleader, Pleasanton, CA, USA).
scF silencing
Stem cell factor silencing was performed by transfecting BMdDCs 
with Lipofectamine® RNAiMax reagent (Invitrogen, Thermo 
Fisher Scientific) using the following siRNAs: SCF-siRNA 
(sc-39735, consisting of a pool of three target-specific 19–25 nt 
siRNA), scrambled control-A siRNA (sc-37007), fluorescein 
conjugated control-A siRNA (sc-36869), all from Santa Cruz 
(Dallas, TX, USA).
cell Viability assay by Flow cytometry
Stem cell factor- or control-silenced BMdDCs were cultured 
for 2 days in 96-well plates at 2 × 105/well in complete Opti-
MEM medium with or w/o GM-CSF at 20 ng/ml. Cells were 
then collected, stained with Annexin V FITC and PI, and 
analyzed by flow cytometry. In experiments with blocking anti-
c-kit mAb, BMdDCs were cultured as above in the presence 
of 10  µg/ml of either anti-c-kit (ACK2) or isotype control 
(RTK4530) mAb (both Low Endotoxin Azide Free, Biolegend). 
After 2  days, cells were collected and analyzed by Annexin 
V FITC/PI as above.
cell number Determination
BM-derived DC numbers were determined by the CyQUANT 
Cell Proliferation Assay kit from Invitrogen according to manu-
facturer’s instructions. Optical density was determined using a 
VICTOR X Multilabel Plate Reader.
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human BM samples collection and Flow 
cytometric analysis
Pieces of spongy bone, which would otherwise have been 
discarded, were obtained from systemically healthy patients 
undergoing hip replacement at either Centro Traumatologico 
Ortopedico Andrea Alesini Hospital or Policlinico Tor Vergata, 
Rome, after approval by Institutional Ethics Committee, 
and informed consent from patients in accordance with the 
Declaration of Helsinki (study no. 129.14, prot 76699 and 
study no. 156.15, prot. 0030053/2015). BM mononuclear cells 
were  isolated by Lympholyte-H (Cedarlane, NC, USA) density- 
gradient centrifugation. Flow cytometry was performed as above, 
using FcR Blocking Reagent and Dead Cell Discrimination Kit 
(Mitenyi Biotec) before addition of the following fluorochrome-
conjugated mAbs: CD1c or BDCA-1 (AD5-8E7), CD141 or 
BDCA-3 (AD5-14H12), CD45 (2D1) CD14 (TÜK4), CD19 
(LT19), c-kit (104D2) [from BD Biosciences; Miltenyi Biotec; 
Exbio, Prague, Czech Republic; conjugated with phycoerythrin 
(PE), PerCP-Vio700, PE-Cy7, APC, APC-H7]. Cells were fixed 
with PBS formaldehyde 1.2% before flow cytometric analysis.
statistics
We performed a two-tailed paired Student’s t-test using Prism 
v.6.0f, GraphPad Software (La Jolla, CA, USA). Differences were 
considered significant when *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
resUlTs
c-Kit is expressed by a Fraction of Dcs in 
the BM of WT Mice
We analyzed membrane c-kit expression by BM and spleen DCs 
freshly obtained from untreated C57BL6/J (B6) mice, gating 
on CD11chi MHC-II+ DC as previously described (47). Typical 
flow cytometry profiles are shown in Figure 1A (see Figure S1A 
in Supplementary Material for our gating strategy, based on 
forward and side scatter plots and exclusion of CD3+, NK1.1+, 
and dead cells). While the great majority of spleen DCs expressed 
membrane c-kit, only a small percentage of BM DCs was c-kit+ 
(Figures 1A,B). Results were similar after about 100-fold enrich-
ment of CD11c+ cells by immunomagnetic selection (Figures 
S2A,B in Supplementary Material). c-kit+ DCs were characterized 
by intermediate levels of membrane c-kit, that is <104 fluores-
cence intensity, whereas other cells in spleen and BM were c-kithi 
(Figure  1C). We observed that MHC-II median fluorescence 
intensity (MFI) was higher in BM DCs than in spleen DCs, in 
agreement with previous results (47). Furthermore, MHC-II 
MFI was higher in c-kit+ BM DCs than in c-kit+ spleen DCs 
(Figure 1D).
c-Kit and high cX3cr1 expression by 
BM Dcs are inversely correlated in 
a cX3cr1-gFP reporter Mouse
It was previously shown that most BM DCs are characterized 
by high CX3CR1 expression, using a mouse model in which 
green fluorescence protein (GFP) replaces CX3CR1 by gene 
targeting (47). We analyzed BM DCs from CX3cr1gfp/+ mice by 
flow cytometry to investigate c-kit expression in respect to GFP 
intensity. We found that c-kit was expressed by the few inter-
mediate green but not by the large population of bright green 
BM DCs from CX3cr1gfp/+ mice (Figure  1E), whereas in the 
spleen most CX3cr1gfp/+ spleen DCs were c-kit+ and had inter-
mediate green fluorescence intensity (Figure 1E). Furthermore, 
CX3CR1-deficient CX3cr1gfp/gfp BM DCs contained a significantly 
higher percentage of c-kit+ cells than WT BM DCs, while the 
percentage of c-kit+ cells within spleen DCs was similar in WT, 
CX3cr1gfp/+, and CX3cr1gfp/gfp mice (Figure 1F; Figures S2C,D in 
Supplementary Material). These results suggest that c-kit expres-
sion and high levels of CX3CR1 are inversely correlated in BM 
DCs and that the presence of c-kit+ DCs in the BM does not 
depend on CX3CR1 expression.
c-Kit is expressed by all cDc1s and by a 
Fraction of cDc2s in the BM of WT Mice
We then performed flow cytometric analysis of cDC subsets 
from spleen and BM of WT mice, by gating on either cDC1s 
or cDC2s, based on CD8α and CD11b expression (14, 48). We 
found that virtually all cDC1s and a small proportion of cDC2s 
expressed c-kit in the BM, whereas both cDC subsets were c-kit+ 
in the spleen (Figures  2A,B). The difference in c-kit percent-
ages between BM cDC1s and cDC2s was statistically significant 
(Figure  2C). In the BM, c-kit+ DCs expressed intermediate 
levels of CD11b, while c-kit− DCs were CD11bhi (Figure  2A, 
right top panel).
an In Vitro culture system to analyze 
c-Kit expression by Mouse BMdDcs
We compared c-kit membrane expression by DCs obtained 
from mouse BM cells differentiated in  vitro with either 
GM-CSF or Flt3-L (40–42). Both protocols resulted in a small 
percentage of c-kit+ within CD11c+ cells (Figures S3B,D in 
Supplementary Material; gating strategy in Figures S3A,C 
in Supplementary Material). However, DCs generated with 
GM-CSF were characterized by increased cell yield and higher 
cell viability (Figures S3A–D in Supplementary Material and 
data not shown). Thus, we decided to use GM-CSF for further 
experiments and to magnetically select CD11c+ cells from the 
fraction including non-adherent and slightly adherent cells 
at day 7 to obtain highly purified DCs (called “BM-derived 
DCs or BMdDCs,” see Figures S3E,F in Supplementary 
Material). On average, 15% of the BMdDCs were MHC-IIhi 
CD40hi CD11bint and 76% MHC-IIint CD40int CD11bhi cells (see 
example in Figure  3A, top panel). c-kit was expressed only 
by the MHC-IIhi CD40hi cells, suggesting that it is a marker 
of the more mature cells (Figure  3B, top panels). The c-kit+ 
BMdDCs were all CD11bint, whereas the remaining c-kit− cells 
were CD11bhi (Figure 3C, top panel).
To increase the proportion of c-kit+ cells, we replated BMdDCs 
in different culture conditions, all with GM-CSF at 20  ng/ml, 
and then analyzed their membrane phenotype (Figures S4A,B 
in Supplementary Material and data not shown). After 2  days 
of culture in complete Opti-MEM medium, the majority of 
FigUre 1 | c-Kit membrane expression by bone marrow (BM) and spleen dendritic cells (Dcs). BM and spleen cells were obtained from untreated mice, 
stained with fluorochrome-conjugated monoclonal antibodies (mAbs), and analyzed by flow cytometry (for gating strategy see Figure S1 in Supplementary Material). 
(a–D) DCs from wild-type C57BL6/J (B6) mice. (a) Typical flow cytometric profiles, showing c-kit+ cell percentages among CD11chigh MHCII+ DCs. In the 
histograms, solid lines represent c-kit staining profiles, dashed lines isotype control mAb. Numbers represent percentages of cells in the indicated regions. (B) 
Summary of results obtained from BM and spleen of individual mice and average values of each organ (bar). Percentages of c-kit+ cells were obtained after 
subtracting background values with isotype control mAb. (c) Representative dot plots showing c-kit expression by CD11chigh cells. The numbers represent 
percentages of cells in the indicated upper left and upper right regions. (D) MHC-II median fluorescence intensity (MFI) in DCs and c-kit+ DCs from either BM or 
spleen, gated as in (a). Summary of results obtained from BM and spleen of individual mice and average values of each organ (bar). (e–F) DCs from Cx3cr1-
genetically modified mice. (e) Typical flow cytometric profiles, showing c-kit and green fluorescence protein (GFP) expression by CD11chigh MHCII+ DCs from 
Cx3cr1gfp/+ mice, gated as in (a). In the histograms, filled lines represent Cx3cr1gfp/+ DCs, empty lines WT DCs. (F) Summary of results obtained from BM and spleen 
of individual Cx3cr1gfp/+, Cx3cr1gfp/gfp, and WT mice and average values of each group (bar). Percentages of c-kit+ cells were obtained after subtracting background 
values with isotype control mAb. See Figure S2 in Supplementary Material for typical DC flow cytometric profiles of Cx3cr1-genetically modified mice. In (a,c,e) 
representative data of N = 3–7 in 3–6 experiments, in (B,D) N = 7 in six experiments, in (F) N = 9 in three experiments (1 mouse/group in each experiment) 
(***P ≤ 0.001; **P ≤ 0.01).
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BMdDCs were MHC-IIhi CD40hi CD11bint, and expressed c-kit+ 
(Figures  3A–C, bottom panels). Membrane c-kit fluorescence 
intensity significantly increased within the MHC-IIhi CD40hi 
cells, while the MHC-IIint CD40int cells remained negative for 
this marker (Figures  3B,D). c-kit mRNA expression increased 
significantly, indicating that membrane c-kit up-regulation 
depended on increased transcription (Figure 3E).
We usually collected non-adherent and slightly adherent 
BMdDCs when we harvested cells 2  days after replating. In 
some experiments, we separately analyzed adherent cells and 
found that they comprised a higher proportion of MHC-IIint 
CD40int cells compared to the floating fraction of BMdDCs. 
Nevertheless, a high percentage (>70%) of adherent cells was 
still MHC-IIhi CD40hi, confirming that MHC-IIhi CD40hi cells 
represented the large majority of BMdDCs after 2 days of cul-
ture in our conditions (Figure S4C in Supplementary Material). 
Notably, as for the non-adherent fraction, the MHC-IIhi CD40hi 
cells were the only c-kit+ cells in the adherent fraction (Figure 
S4D in Supplementary Material).
scF/c-Kit axis is Functional in BMdDcs 
and Does not influence OVa Presentation 
by BMdDcs
To determine whether c-kit could function as a signal transduc-
ing receptor, c-kit+ BMdDCs were stimulated with SCF and 
FigUre 3 | BM-derived Dcs (BMdDcs) express a functional c-kit 
receptor. BMdDCs were obtained by purifying CD11c+ cells from bone 
marrow cells cultured with granulocyte-macrophage colony-stimulating 
factor (GM-CSF) for 1 week, as explained in Section “Materials and 
Methods” (day 0). BMdDCs were plated in 24-well plates and cultured for 
2 days in complete Opti-MEM medium with GM-CSF at 20 ng/ml (day 2). 
(a–D) Analysis of c-kit membrane expression by flow cytometry. Day 0 
and day 2 BMdDCs were stained with fluorochrome-conjugated 
monoclonal antibodies (mAbs) and analyzed by flow cytometry (for gating 
strategy, see Figure S3 in Supplementary Material). (a) Typical flow 
cytometric profiles showing CD40, CD11b, and MHCII expression by 
BMdDCs. In the left panels, numbers represent percentages of cells in 
the indicated regions. (B) Typical histograms showing c-kit expression by 
MHCIIint CD40int and MHCIIhi CD40hi BMdDCs, gated as in (a). Solid lines 
represent c-kit staining profiles, dashed lines isotype control mAb. 
Numbers indicate c-kit median fluorescence intensity (MFI) values. (c) 
Representative contour plots showing c-kit and CD11b expression by 
BMdDCs. (D) Summary of c-kit expression results obtained from day 0 
and day 2 MHCIIhi CD40hi BMdDCs, gated as in (a). c-kit MFI from 
individual samples and average values (bar). (e) Analysis of c-kit mRNA 
expression by Real-Time PCR. Day 0 and day 2 BMdDC samples were 
analyzed by Real-Time PCR in triplicates. c-kit mRNA expression was 
calculated relative to hprt1 in arbitrary units. For each experiment, day 2 
c-kit/hprt1 levels were normalized with day 0. (F,g) Western blot analysis 
of phospho-AKT expression by BMdDCs stimulated with stem cell factor 
(SCF). Day 2 BMdDCs obtained as above were stimulated with SCF at 
100 ng/ml for 5 and 15 min or left untreated, as indicated. Western blot 
was performed with anti-phospho-AKT, anti-AKT and anti-β actin mAbs, 
and results analyzed by densitometry. (F) Representative Western blot 
results. (g) Densitometric analysis. Phospho-AKT levels were calculated 
relative to AKT in arbitrary units. In (a–c) representative data of 9–16 
experiments, in (D) N = 16 experiments, in (F) representative data of 
three experiments, in (e,g) mean ± SD of three experiments (*P ≤ 0.05; 
***P ≤ 0.001).
FigUre 2 | c-Kit membrane expression by bone marrow (BM) and 
spleen type 1 cDc subsets (cDc1s) and type 2 cDc subsets (cDc2s). 
BM and spleen cells were obtained from untreated B6 mice, stained with 
fluorochrome-conjugated monoclonal antibodies (mAbs), and analyzed by 
flow cytometry. CD11chigh MHCII+ dendritic cells (DCs) were gated for analysis 
as in Figure 1a. (a) Typical flow cytometric profiles, showing c-kit, CD8α, 
and CD11b expression by DCs. In histograms, solid lines represent c-kit 
staining profiles, dashed lines represent isotype control mAb. The numbers 
represent percentages of cells in the indicated regions. (B) Representative 
histograms showing percentages of c-kit+ cells among cDC1s and cDC2s, 
gated as shown. (c) Percentages of c-kit+ cells among cDC1s and cDC2s 
from either BM or spleen of individual mice and average values of each organ 
(bar). In (a,B) representative data of N = 4 in three experiments, panel (c) 
N = 4 in three experiments (***P ≤ 0.01).
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analyzed for phosphorylated Akt, a serine-threonine kinase 
located downstream of PI3-kinase with an essential role in cel-
lular survival and proliferation (34). After incubation with SCF, 
phospho-Akt levels increased rapidly, while total Akt remained 
unchanged (Figures 3F,G).
FigUre 4 | antigen presentation by BM-derived Dcs (BMdDcs) is not modulated by stem cell factor (scF). Day 2 BMdDCs, obtained as in Figure 3, 
were incubated for 5 h with OVA at 0.2 mg/ml, in the presence or not of SCF at 100 ng/ml. After extensive washings, BMdDCs were cocultured with either 
CFSE-labeled purified OT-1 or CFSE-labeled purified OT-2 cells for 3 days. CSFE dilution was evaluated by flow cytometry, (a,c) Typical CSFE profiles, after 
gating on TCR+ CD8+ for OT-1 (a) and TCR+ CD4+ for OT-2 T cells (c). Numbers represent percentages of cells in the indicated regions. (B,D) Summary of OT-1 
(B) and OT-2 (D) proliferation results from individual samples and average values (bar). In (a,c) representative data of N = 3 experiments, in (B,D) N = 3 
experiments (*P ≤ 0.05; **P ≤ 0.01).
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To evaluate the effect of SCF on the capacity of c-kit+ 
BMdDCs to present the model antigen OVA, we assessed the 
proliferation of OVA-specific T cells from TCR transgenic mice 
OT-1 and OT-2, by CFSE dilution. We observed that both OT-1 
(Figures 4A,B) and OT-2 (Figures 4C,D) cells proliferated in 
response to BMdDCs preincubated with OVA, showing the 
functionality of both MHC-I and MHC-II presentation path-
ways. The presence of SCF during preincubation of BMdDCs 
with OVA did not influence the proliferation of neither OT-1 
(Figures 4A,B) nor OT-2 (Figures 4C,D) cells.
gM-csF inhibits c-Kit Membrane 
expression by BMdDcs
Since GM-CSF can inhibit c-kit expression by mast cells (49, 50), 
we next evaluated the effects of GM-CSF in our BMdDC cultures, 
by comparing c-kit membrane expression by BMdDCs cultured 
in complete Opti-MEM medium either with or without GM-CSF 
at 20 ng/ml. Furthermore, considering the possible intercellular 
competition for GM-CSF, we cultured BMdDCs at two different 
cell densities, i.e., about 6.3 × 105 and 1 × 105 cells/cm2, corre-
sponding to 1.2 × 106 and 0.2 × 106 cells/well in 24-well plate, 
respectively. We observed that c-kit membrane expression by 
MHC-IIhi CD40hi cells was higher when BMdDCs were cultured 
at higher cell density, and in particular, MHC-IIhi CD40hi cells 
had extremely high c-kit fluorescence intensity when cultured 
without GM-CSF if compared to BMdDCs cultured in the pres-
ence of GM-CSF (Figures 5A–C).
Stem cell factor can be produced by a variety of cell types, 
including DCs (25, 29, 30). We found that BMdDCs produced 
cell-associated SCF and its levels remained stable after 2  days 
of culture in complete Opti-MEM medium with GM-CSF. 
When BMdDCs were cultured in the absence of GM-CSF, 
cell-associated SCF significantly increased (Figure  5D). SCF 
concentration in supernatants was 50.33  ±  1.05  pg/ml after 
2  days of culture in the presence of GM-CSF and did not 
increase in the absence of GM-CSF (data not shown). Notably, 
FigUre 5 | granulocyte-macrophage colony-stimulating factor (gM-csF) modulates c-kit and stem cell factor (scF) expression by BM-derived 
Dcs (BMdDcs). (a–c) Effect of GM-CSF and cell density on c-kit expression by BMdDCs. BMdDCs were plated in 24-well plates and cultured for 2 days in 
complete Opti-MEM medium in four different conditions, that is at either 2 × 105 or 1.2 × 105 cell/well, and either with or without (w/o) GM-CSF at 20 ng/ml, as 
indicated. Cells were stained with fluorochrome-conjugated monoclonal antibodies (mAbs) and analyzed by flow cytometry. (a) Typical flow cytometric profiles, 
showing CD40 and MHCII expression by BMdDCs. Numbers represent percentages of cells in the indicated regions. (B) Typical histograms showing c-kit 
expression by MHCIIint CD40int and MHCIIhi CD40hi BMdDCs, gated as in (a). Solid lines represent c-kit staining profiles, dashed lines represent isotype control 
mAb. Numbers indicate c-kit median fluorescence intensity (MFI) values. (c) Summary of c-kit expression results obtained from MHCIIhi CD40hi BMdDCs, gated as 
in (a). c-kit MFI from individual samples and average values (bar). (D,e) Effect of GM-CSF on SCF expression by BMdDCs. (D) Cell lysates were prepared from day 
0 BMdDCs and BMdDCs cultured for 2 days in 24-well plates at 1.2 × 105 cell/well in complete Opti-MEM medium with or w/o GM-CSF at 20 ng/ml, as indicated. 
SCF protein expression was analyzed by ELISA, testing 25 µg of cell lysate in 100 µl/well. Data are expressed as picograms per milliliter. Individual results from 
three experiments and average values (bar) are shown. (e) Day 0 and day 2 BMdDCs cultured in 24-well plates at 1.2 × 105 cell/well with or w/o GM-CSF at 
20 ng/ml were analyzed by Real-Time PCR in triplicates. SCF mRNA expression was calculated relative to hprt1 in arbitrary units. For each experiment, day 2 c-kit/
hprt1 levels were normalized with day 0. In (a,B) representative data of N = 4 experiments, in (c) N = 4 experiments, in (D) N = 3 experiments, in (e) mean ± SD 
of four experiments (*P ≤ 0.05; **P ≤ 0.01).
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SCF expression increased at the mRNA level when BMdDCs 
were cultured for 2  days without GM-CSF (Figure  5E). Thus, 
BMdDCs can produce SCF, but the presence of GM-CSF 
interferes with this process.
scF Does not Modulate cXcr4 
Membrane expression by BMdDcs
CXCR4 plays a key role in leukocyte retention in the BM, 
by interacting with CXCL12 (51). Moreover, DC maturation 
results in upregulation of CXCR4 (3, 5). We compared CXCR4 
membrane expression by BMdDCs cultured in complete Opti-
MEM medium either with or without GM-CSF at 20 ng/ml and 
evaluated whether an overnight addition of SCF to these cultures 
modulated CXCR4. MHC-IIhi CD40hi cells had always a higher 
CXCR4 MFI than MHC-IIint CD40int cells (Figures 6A,B). CXCR4 
expression by MHC-IIhi CD40hi cells increased in the absence of 
GM-CSF, and the addition of SCF to the culture did not influence 
the expression of CXCR4 (Figures 6B,C).
FigUre 6 | granulocyte-macrophage colony-stimulating factor (gM-csF) but not stem cell factor (scF) modulates cXcr4 expression by BM-
derived Dcs (BMdDcs). BMdDCs were plated in 24-well plates and cultured for 2 days in complete Opti-MEM medium either with or without (w/o) GM-CSF at 
20 ng/ml. SCF was then added at 100 ng/ml and cells were further incubated for 16 h. Cells were stained with fluorochrome-conjugated monoclonal antibodies and 
analyzed by flow cytometry. (a) Typical CD40 and MHCII expression profiles. Numbers represent percentages of cells in the indicated regions. (B) Typical histograms 
showing CXCR4 expression by MHCIIint CD40int and MHCIIhi CD40hi BMdDCs, gated as in (a). Solid lines represent CXCR4 staining profiles, dashed lines represent 
no Ab (FMO, Fluorescence Minus One). Numbers indicate CXCR4 median fluorescence intensity (MFI) values. (c) Summary of CXCR4 expression results obtained 
from MHCIIhi CD40hi BMdDCs, gated as in (a). CXCR4 MFI from individual samples and average values (bar). In (a,B) representative data of N = 4 experiments, in 
(c) N = 4 experiments (**P ≤ 0.01; ***P ≤ 0.01).
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scF is an autocrine survival Factor for 
BMdDcs
To evaluate whether BMdDC survival could be modulated 
by SCF autocrine production, SCF was silenced by transfec-
tion with SCF-siRNA and cell survival analyzed after 2  days 
of culture either with or without GM-CSF. In our conditions, 
transfection efficiency was about 40%, as evaluated in control 
cells transfected in parallel with fluorescein-conjugated RNA, 
and SCF protein concentration in lysates from SCF-siRNA-
silenced cells was about 70% than that in lysates from scrambled 
siRNA-silenced control cells (e.g., 489  pg/ml in SCF-silenced 
cells and 671 pg/ml in control cells, in cultures with GM-CSF; 
589 pg/ml in SCF-silenced cells and 714 pg/ml in control cells, 
without GM-CSF). Although SCF expression was only partially 
reduced, we observed a statistically significant decrease in cell 
survival in the cultures with GM-CSF, based on Annexin V/PI 
staining (Figures 7A,B). Absolute cell numbers were significantly 
decreased upon SCF silencing in both BMdDC cultures, with and 
without GM-CSF (Figure 7C). In a different set of experiments, 
we cultured BMdDCs for 2 days in the presence of 10 µg/ml of 
either the anti-c-kit blocking mAb ACK2 or its corresponding 
control mAb and observed a modest but statistically significant 
decrease in cell survival, based on Annexin V/PI staining (Figure 
S5 in Supplementary Material). Results were similar in BMdDC 
culture with and without GM-CSF (Figure S5 in Supplementary 
Material). Altogether, these findings indicate that DCs promote 
their own survival both by the autocrine production of SCF and 
by expressing the receptor c-kit.
c-Kit is Preferentially expressed by cDc1s 
in human BM
We also analyzed cDC from human BM samples, by using high 
levels of CD141 and expression of CD1c as markers for cDC1s 
and cDC2s, respectively (14, 52). Typical examples of human BM 
FigUre 7 | negative effect of stem cell factor (scF) silencing on BM-derived Dc (BMdDc) survival. BMdDCs were transfected with either SCF-siRNA or 
control-scrambled (scrl) siRNA, or else left untreated. Cells cultured in triplicates in 96-well plates at 2 × 105/well in complete Opti-MEM medium with or w/o 
granulocyte-macrophage colony-stimulating factor (GM-CSF) at 20 ng/ml were analyzed after 2 days. (a,B) Percentages of living cells. Flow cytometry analysis was 
performed after staining with Annexin V FITC and incubation with PI. (a) Typical Annexin V and PI staining profiles. Numbers represent percentages of cells in the 
indicated quadrants. Living cells are in the lower left quadrant (Annexin V− PI−). (B) Summary of results obtained by analyzing living cell percentages among 
SCF-siRNA and control-scrambled siRNA treated BMdDCs, gated as in (a). Percentages of living cells from individual samples and average values (bar). (c) 
Numbers of living cells. BMdDC numbers were evaluated by the CyQuant assay. Results of SCF-siRNA and control-scrambled siRNA treated samples were 
normalized over corresponding untreated BMdDCs. Numbers of living cells from individual samples and average values (bar). In (a) representative data of N = 5 
experiments, in (B,c) N = 5 experiments (*P ≤ 0.05).
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cytometric profiles are shown in Figures 8A,B (gating strategy 
in Figure S1B in Supplementary Material). In agreement with 
mouse data, we found that cDC1s contained a significantly higher 
percentage of c-kit+ cells than cDC2s (Figure 8C). c-Kit histo-
grams suggested that cDC1s represented a homogeneous subset 
expressing c-kit at low levels, rather than a heterogeneous popula-
tion containing a negative and a positive fraction (Figure 8A). 
Further analysis showed that the CD141− fraction in the BM 
contained cells expressing much higher c-kit levels than cDC1s 
(Figure 8B).
FigUre 8 | c-Kit membrane expression by human bone marrow (BM) type 1 cDc subsets (cDc1s) and type 2 cDc subsets (cDc2s). Single-cell 
suspensions were prepared from human BM samples obtained from patients undergoing orthopedic surgery. After density gradient, cells were stained with 
fluorochrome-conjugated monoclonal antibodies (mAbs) and analyzed by flow cytometry (for gating strategy, see Figure S1B in Supplementary Material). (a) Typical 
flow cytometric profiles, showing c-kit+ cell percentages among CD141hi cDC1s and CD1c+ cDC2s. In histograms, solid lines represent c-kit staining profiles, 
dashed lines represent no Ab (FMO). The numbers represent percentages of cells in the indicated regions. (B) Representative contour plots showing c-kit, CD141, 
and CD1c expression by BM cells. The numbers represent percentages of cells in the indicated regions. (c) Summary of results obtained from BM of individual 
patients and average values of each group (bar). Percentages of c-kit+ cells were obtained after subtracting FMO background values. In (a,B) representative data of 
N = 3 in three experiments, in (c) N = 3 in three experiments (*P ≤ 0.05).
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DiscUssiOn
Our data show that c-kit+ DCs are found in human BM, and 
mouse spleen and BM. BM c-kit+ DCs had intermediate expres-
sion of GFP in the CX3cr1gfp/+ reporter mouse, distinguishing 
them from the previously described perivascular BM-resident 
DC subset (47). By comparing the two cDC subsets in the BM, 
we found that both human and mouse BM cDC1s were homo-
geneous cell populations, expressing low and intermediate 
levels of c-kit, respectively, whereas cDC2s were heterogeneous 
and differed between humans and mice. c-Kit was expressed 
by a fraction of mouse BM cDC2s, while human BM cDC2s 
had little or no expression of c-kit, thus echoing human blood 
cDC2s (53). The difference in c-kit expression between BM 
cDC1s and cDC2s is not surprising, in light of the distinct 
developmental pathways and composition of these two subsets. 
Indeed, cDC1s are more homogeneous and their development 
strongly requires the transcription factor BATF3, while cDC2s 
mostly depend on IRF4 and comprise various subpopulations 
(2, 14). In further support of cDC2 heterogeneity, we found 
that—differently from mouse BM cDC2s—mouse spleen cDC2s 
were virtually all c-kit+.
c-kit+ DCs represented a small percentage of DCs differenti-
ated from mouse BM cells in vitro with either Flt3-L or GM-CSF. 
It is known that DCs differentiated from BM cells with GM-CSF 
are heterogeneous for the expression of typical activation mark-
ers, e.g., MHC-II, CD40 (54, 55). We followed a widely used 
protocol to generate DCs (41), and after purification of CD11c+ 
cells at day 7, we obtained a mixture of c-kit− CD40int MHC-IIint 
and c-kit+ CD40hi MHC-IIhi cells. However, after replating these 
BMdDCs in complete Opti-MEM medium with GM-CSF for 
2  days, we obtained a quite homogeneous set of c-kit+ CD40hi 
MHC-IIhi cells, which expressed a functional c-kit receptor, as 
demonstrated by Akt phosphorylation after a short incubation 
with SCF. Upon incubation with the model antigen OVA, these 
cells were able to present OVA-derived peptides to both OT-1 
and OT-2 cells, showing that both MHC-I and MHC-II antigen 
presentation pathways were functional. Results were similar with 
or without SCF. We also investigated whether CXCR4 expression 
by BMdDCs could be modulated by GM-CSF and/or SCF and 
observed that GM-CSF negatively regulated CXCR4 membrane 
expression, while SCF did not have any effect. This suggests that 
SCF does not regulate retention of DCs in the BM, while GM-CSF 
might promote DC mobilization out of the BM, by reducing 
CXCR4 expression. GM-CSF-mediated inhibition of CXCR4 
expression by DCs resembles GM-CSF effect on neutrophils (56).
We documented a negative effect of GM-CSF on both c-kit 
expression and SCF production by BMdDCs. Indeed, c-kit 
expression strikingly increased if GM-CSF was omitted after 
replating BMdDCs in complete Opti-MEM. We also observed 
that c-kit expression significantly increased at high cell density 
with GM-CSF at 20  ng/ml, possibly reflecting reduced avail-
ability of GM-CSF due to intercellular competition in the 
culture. The fact that, even without adding GM-CSF, high-
density BMdDC cultures resulted in increased c-kit expression 
suggests that further mechanisms regulate c-kit expression, for 
example, changes in pH, or competition for nutrients in the 
medium. Furthermore, we showed that BMdDCs produced SCF 
and that both SCF mRNA and protein augmented when cells 
were cultured without GM-CSF for 2  days after replating. In 
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particular, cell-associated SCF increased, but not SCF found 
in the culture supernatant, suggesting either that membrane-
bound SCF was the prevalent isoform or that soluble SCF was 
consumed in the culture.
The inverse correlation between addition of GM-CSF to 
the culture medium and expression of c-kit/SCF by BMdDCs 
prompted us to investigate whether autocrine SCF production 
could play a role in BMdDC survival. In this regard, we found that 
SCF silencing by siRNA resulted in reduced BMdDC survival, 
suggesting that SCF could contribute to DC maintenance. The 
prosurvival role of SCF in DC survival has not been previously 
recognized, possibly due to the inhibitory effects of GM-CSF 
on SCF/c-kit axis. Indeed, it should not be overlooked that 
GM-CSF is widely employed to culture mouse and human DCs 
in vitro, including human DCs used in clinical settings (57–59). 
Based on our study, alternative methods to culture differentiated 
DCs in vitro might be developed, possibly exploiting SCF/c-kit 
circuit (60–62).
We speculate that DCs more prominently rely on SCF in vivo 
in some microenvironments, for example, in conditions of low 
GM-CSF and high SCF concentration, that might be found in 
some BM niches. To obtain evidence of SCF/c-kit function in 
differentiated DCs in  vivo, it would be necessary to develop 
new models of genetically manipulated mice, as available 
mutant mice have major developmental defects. Indeed, genetic 
deficiencies in either c-kit or SCF are often lethal in mice, or 
can lead to severe defects of hematopoiesis, melanocyte, and 
germ cell development (63, 64), making it difficult to examine 
DCs. In case of hypomorphic c-kit mutations, myeloid lineage 
defects were not usually reported (65), nevertheless the absolute 
number of CMPs was significantly decreased in mice bearing 
the W41 hypomorphic mutation (66), suggesting an abnormal 
development of CMP-derived cells, including DCs. Notably, 
c-kit is expressed not only by CMPs, but also by common DC 
precursors in the BM (24, 67, 68). Thus, novel tools have to 
be developed to specifically investigate the role of SCF/c-kit 
in differentiated DC survival, for example, DC-specific c-kit 
conditional ko mice.
Our results on c-kit+ BM DCs might be relevant for some 
hematological diseases in which immune responses occur in 
the BM, such as graft-versus-host disease (GVHD) and graft-
versus-leukemia (69–71). It is now recognized that the BM niche 
for HSC is one of the major targets of GVHD, in addition to 
gut, liver, and skin (70–72). In this context, local DCs in the 
BM can orchestrate T cell activation (73), thus regulating target 
organ damage. Based on our results, it might be speculated that 
changes in BM SCF levels occurring in BM transplantation (74, 
75) can affect DC survival, possibly influencing several steps 
of local and systemic immune response. Moreover, a reduced 
expression of either SCF or c-kit might play a role in BM DC 
survival in some diseases of unclear pathogenesis, for example 
high-risk myelodysplastic syndromes (76), and sepsis-induced 
immunosuppression (77, 78).
Notably, c-kit+ DCs have been implicated in the immune 
response against cancer, but their role is still unclear. On one hand, 
it was proposed that some indirect anticancer effects of therapy 
with imatinib mesylate might be due to drug-mediated inhibition 
of c-kit and/or other tyrosine kinase receptors expressed by DCs 
(79). On the other hand, microarray analysis of intratumoral 
DCs  from cancers with different prognosis intriguingly dem-
onstrated that the top gene positively correlated with favorable 
prognosis is c-kit (80). Thus, further studies are required to deter-
mine the role of c-kit+ DC, including BM cDC1s, in orchestrating 
either spontaneous or treatment-induced antitumor immunity.
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FigUre s1 | gating strategy for mouse and human dendritic cells (Dcs). 
Cells were stained with fluorochrome-conjugated monoclonal antibodies and 
analyzed by flow cytometry. (a) Mouse bone marrow (BM) and spleen DCs. 
Gating strategy based on forward and side scatter is shown. In the dump 
channel, CD3+, NK1.1+, and PI+ cells were excluded. (B) Human BM DCs. 
Gating strategy based on forward and side scatter is shown. The CD45+ cells 
were gated, while CD14+, CD19+, and dead cell discriminator (DCD)+ cells were 
excluded in the dump channel.
FigUre s2 | c-Kit membrane expression by dendritic cells (Dcs) from WT 
and cx3cr1-genetically modified mice. (a,B) CD11c+ cells were enriched 
from WT bone marrow (BM) and spleen by immunomagnetic selection. (c,D) BM 
and spleen cells were obtained from Cx3cr1gfp/+, Cx3cr1gfp/gfp, and WT mice. Cells 
were stained with fluorochrome-conjugated monoclonal antibodies (mAbs) and 
analyzed by flow cytometry. Typical flow cytometric profiles, showing c-kit+ cell 
percentages among CD11chigh MHCII+ DCs from BM (a,c) and spleen (B,D). In 
the histograms, solid lines represent c-kit staining profiles, dashed lines isotype 
control mAb. Numbers represent percentages of cells in the indicated regions. In 
(a,B) representative data from N = 5 experiments, in (c,D) representative data 
from N = 9 in three experiments (1 mouse/group in each experiment).
FigUre s3 | gating strategy for dendritic cells (Dcs) generated in vitro 
from mouse bone marrow (BM). Cells were stained with fluorochrome-
conjugated monoclonal antibodies (mAbs) and analyzed by flow cytometry. 
Gating strategy based on forward/side scatter and dead cell exclusion by PI is 
shown for DCs generated from BM cells with FMS-like tyrosine kinase 3 ligand 
(Flt3-L) (a) and with granulocyte-macrophage colony-stimulating factor 
(GM-CSF) (c,e). c-kit expression is shown for DCs generated with Flt3-L (B) and 
with GM-CSF (D,F). Panels (e,F) show results obtained with GM-CSF after cell 
purification with anti-CD11c magnetic microbeads. Histograms show results 
obtained with CD11c+ cells, gated as shown; solid lines represent c-kit staining 
profiles, dashed lines indicate isotype control mAb.
FigUre s4 | c-Kit expression by BM-derived Dcs (BMdDcs): comparison 
of different culture media and analysis of adherent and non-adherent 
cells. (a,B) Culture media. BMdDCs were plated in 24-well plates and cultured 
for 2 days with granulocyte-macrophage colony-stimulating factor (GM-CSF) at 
20 ng/ml either in complete RPMI medium, or in complete Opti-MEM medium. 
Complete RPMI medium contains 10% fetal calf serum (FCS); complete 
Opti-MEM medium is serum free (see Section “Materials and Methods” for 
details). Cells were stained with fluorochrome-conjugated monoclonal antibodies 
(mAbs) and analyzed by flow cytometry, as in Figure 3. (a) Typical flow 
cytometric profiles, showing CD40 and MHCII expression by BMdDCs. Numbers 
represent percentages of cells in the indicated regions. (B) Typical histograms 
showing c-kit expression by MHCIIint CD40int and MHCIIhi CD40hi BMdDCs, gated 
as in (a). Solid lines represent c-kit staining profiles, dashed lines indicate isotype 
control mAb. Numbers indicate c-kit median fluorescence intensity values. 
(c,D) Adherent and non-adherent cells. BMdDCs were plated in 24-well plates 
and cultured for 2 days in complete Opti-MEM medium with GM-CSF at 20 ng/
ml, before harvesting either non-adherent cells or adherent cells after 
detachment with PBS 10 mM EDTA. Cells were analyzed and results 
represented as in (a,B). In (a,B) representative data from N = 3 experiments; in 
(c,D) representative data from N = 5 experiments.
FigUre s5 | negative effect of anti-c-kit blocking monoclonal antibody 
(mab) on BM-derived Dc (BMdDc) survival. BMdDCs were cultured for 
2 days in triplicates in 96-well plates at 2 × 105/well in complete Opti-MEM 
medium in four different conditions, that is either with or without (w/o) granulocyte-
macrophage colony-stimulating factor (GM-CSF), and in the presence of 10 µg/ml 
of either the anti-c-kit blocking mAb ACK2 or its isotype control (ctrl) mAb, as 
indicated. Flow cytometry analysis was performed after staining with Annexin V 
FITC and incubation with PI. (a) Typical Annexin V and PI staining profiles. 
Numbers represent percentages of cells in the corresponding quadrants. Living 
cells are in the lower left quadrant (Annexin V− PI−). (B) Summary of results. 
Percentages of living cells from individual samples treated either with anti-c-kit or 
control mAb. In (a) representative data of N = 4 experiments, in (B) N = 4 
experiments (*P ≤ 0.05).
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